
Viking Therapeutics (VKTX) Stock Forecast & Price Target
Viking Therapeutics (VKTX) Analyst Ratings
Bulls say
Viking Therapeutics is a healthcare service provider with an established drug development company in the area of biopharmaceutical development, focused on metabolic and endocrine disorders. The company's multiple avenues to drive adoption, expanding access through alternative PBM relationships, and a single molecule strategy across oral and injectable formats represent important differentiators for VK2735, VK2809, and VK0214. With a strong cash runway and openness to BD discussions, Viking Therapeutics is well positioned to maintain strategic flexibility while advancing its pipeline.
Bears say
Viking Therapeutics is facing legal challenges and difficulties in advancing their product due to disputes with LGND. Their products, although promising, face competition in development and on the market, as well as potential barriers to entry due to required liver biopsies in Phase 3. Their current cash balance and upcoming Phase 1 study for VK3019 may provide some short-term support, but long-term success is uncertain.
This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Viking Therapeutics (VKTX) Analyst Forecast & Price Prediction
Start investing in Viking Therapeutics (VKTX)
Order type
Buy in
Order amount
Est. shares
0 shares